State Street’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

State Street’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.49M	Buy	1,461,454 +109,830	+8%	+$337K	﹤0.01%	3002
2025 Q4	$4.81M	Buy	1,351,624 +221,599	+20%	+$822K	﹤0.01%	3012
2025 Q3	$3.94M	Buy	1,130,025 +483,768	+75%	+$1.66M	﹤0.01%	3084
2025 Q2	$1.32M	Buy	646,257 +544,957	+538%	+$1.36M	﹤0.01%	3428
2025 Q1	$115K	Hold	101,300	–	–	﹤0.01%	3944
2024 Q4	$31.3K	Hold	101,300	–	–	﹤0.01%	4183
2024 Q3	$33.1K	Hold	101,300	–	–	﹤0.01%	4163
2024 Q2	$46.6K	Hold	101,300	–	–	﹤0.01%	4154
2024 Q1	$160K	Hold	101,300	–	–	﹤0.01%	3924
2023 Q4	$207K	Buy	101,300 +23,300	+30%	+$40.4K	﹤0.01%	3895
2023 Q3	$109K	Buy	78,000 +6,000	+8%	+$6.21K	﹤0.01%	4092
2023 Q2	$39.6K	Sell	72,000 -347,621	-83%	-$184K	﹤0.01%	4474
2023 Q1	$284K	Buy	419,621 +644	+0.2%	+$822	﹤0.01%	3943
2022 Q4	$691K	Buy	418,977 +130,850	+45%	+$367K	﹤0.01%	3657
2022 Q3	$1.33M	Buy	288,127 +89,500	+45%	+$526K	﹤0.01%	3527
2022 Q2	$1M	Buy	198,627 +167,527	+539%	+$1.22M	﹤0.01%	3633
2022 Q1	$222K	Buy	+31,100	New	+$210K	﹤0.01%	4342

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street's STLN Position: Q1 2026 in Review

State Street increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 8.1% in Q1 2026, buying an estimated $337K and bringing the position to 1,461,454 shares worth $4.49M. The position accounts for ﹤0.01% of the portfolio, ranked #3002.

State Street first reported a position in STLN in Q1 2022 and has held it in 17 quarters since. The position peaked at $4.81M in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

State Street held 1,461,454 shares of Starling Oncology Institute, Inc. Common Stock worth $4.49M as of Q1 2026.
State Street bought 109,830 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $337K.
Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3002 holding.
State Street first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2022 and has held it in 17 quarters since.
State Street's Starling Oncology Institute, Inc. Common Stock position peaked at $4.81M in Q4 2025.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.